Call at 8:00 a.m. Eastern Time on Tuesday, March 31, 2020
WALTHAM, Mass., March 24, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of central nervous system (CNS) disorders, today announced that it will host a Key Opinion Leader (KOL) call on roluperidone and the treatment of the negative symptoms of schizophrenia on Tuesday, March 31, 2020.
Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva, will join William T. Carpenter, MD, University of Maryland, Ofer Agid, MD, University of Toronto, John Kane, MD, Hofstra University/ Northwell Health System, and Stephen Marder, MD, UCLA, to discuss the treatment of negative symptoms of schizophrenia.
In the second quarter of 2020, Minerva expects to announce top line results from a Phase 3 study with roluperidone in patients diagnosed with schizophrenia with negative symptoms. Roluperidone is the only molecule in advanced clinical development that to date has shown a specific effect on negative symptoms in schizophrenia.
Tuesday, March 31, 8:00 a.m. Eastern Time
Dr. Carpenter is a Professor of the University of Maryland School of Medicine and past Director of the Maryland Psychiatric Research Center. He is Past-President of the American College of Neuropsychopharmacology and chairs the scientific program committee of the Brain and Behavior Research Foundation. He also chaired the DSM-V Psychosis Work Group.
Dr. Agid is Clinician Scientist and Psychiatrist in the Schizophrenia Program and Medical Head, Ambulatory Services and the Lead Psychiatrist, Partial Hospital Program at the Schizophrenia Program, Centre for Addiction and Mental Health and Associate Professor in the Department of Psychiatry at the University of Toronto.
Dr. Kane is Senior Vice President for Behavioral Health Services of the Northwell Health System. He is Chairman of Psychiatry and Professor of Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. He has chaired review and advisory committees at the NIMH and the Food and Drug Administration and has served as President of the Schizophrenia International Research Society and the American Society of Clinical Psychopharmacology.
Dr. Marder is currently the Director of the Veterans Integrated Service Network 22 Mental Illness Research, Education Clinical Center for the Department of Veterans Affairs and the Director of the Section on Psychosis at the UCLA Neuropsychiatric Institute. He is a Professor and the Vice Chair for Education at the Semel Institute for Neuroscience at UCLA.
About Minerva Neurosciences
Minervas proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinsons disease. Minervas common stock is listed on the NASDAQ Global Market under the symbol NERV. For more information, please visit http://www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect managements expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and scope of future clinical trials and results of clinical trials with roluperidone (MIN-101); the clinical and therapeutic potential of this compound; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and managements ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; managements ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption Risk Factors in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year endedDecember 31, 2019, filed with theSecurities and Exchange Commission on March 9, 2020. Copies of reports filed with theSECare posted on our website at http://www.minervaneurosciences.com. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
Story continues
Contact:William B. BoniVP, Investor Relations/Corp. CommunicationsMinerva Neurosciences, Inc.(617) 600-7376
Read the rest here:
MINERVA NEUROSCIENCES TO HOST KEY OPINION LEADER MEETING ON ROLUPERIDONE: A POTENTIALLY NOVEL MECHANISM TO TREAT THE NEGATIVE SYMPTOMS OF...
- Elusive Cures: Why Neuroscience Hasnt Solved Brain Disordersand How We Can Change That, an excerpt - The Transmitter - June 10th, 2025 [June 10th, 2025]
- Nanowire Retinal Implant Restores Vision and Sees Infrared - Neuroscience News - June 10th, 2025 [June 10th, 2025]
- KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO... - June 10th, 2025 [June 10th, 2025]
- Obeying Orders Lowers Moral Responsibility Perception in the Brain - Neuroscience News - June 10th, 2025 [June 10th, 2025]
- Family Time and Parental Bonding Linked to Better Sleep in Preteens - Neuroscience News - June 10th, 2025 [June 10th, 2025]
- Study Links Gut Bacteria to MS Risk and Reveals Key Triggers - Neuroscience News - June 10th, 2025 [June 10th, 2025]
- Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant... - June 10th, 2025 [June 10th, 2025]
- Sleep-Wake Perception Intact in Many With Insomnia - Neuroscience News - June 10th, 2025 [June 10th, 2025]
- Cannabis Use Among U.S. Seniors Has Surged 46% in Just Two Years - Neuroscience News - June 10th, 2025 [June 10th, 2025]
- Anoki Integrates With Magnite While Seedtag Adds Neuroscience To Find Emotional Connections - TVREV - June 10th, 2025 [June 10th, 2025]
- Neuroscience: Knowing People's Names Makes You Empathize With Them Better. (By the Way, My Name Is Bill) - Inc.com - June 1st, 2025 [June 1st, 2025]
- Kindness Sparks Cooperation by Boosting Social Connectedness - Neuroscience News - June 1st, 2025 [June 1st, 2025]
- Neuroscience and Genetics of ADHD and Neurodevelopment - Neuroscience News - June 1st, 2025 [June 1st, 2025]
- The Neuroscience of Cancer - Harvard Medicine Magazine - June 1st, 2025 [June 1st, 2025]
- Singing to Infants Boosts Mood and Bonding - Neuroscience News - June 1st, 2025 [June 1st, 2025]
- Neuroscience: Go Swimming and Your Brain Will Thank You - Inc.com - June 1st, 2025 [June 1st, 2025]
- Blood Fat Links Found Between Heart Risk and Alzheimers - Neuroscience News - June 1st, 2025 [June 1st, 2025]
- Tiny Brain Cell Cluster Found to Drive Obesity and Overeating - Neuroscience News - June 1st, 2025 [June 1st, 2025]
- New Neuroscience Shows Why Its So Important to Read Aloud to Your Kids - Inc.com - June 1st, 2025 [June 1st, 2025]
- Cats Can Recognize Their Owners by Smell Alone - Neuroscience News - June 1st, 2025 [June 1st, 2025]
- St. Lukes Center for Neuroscience Helps Those with Same Illness as Billy Joel - TAPinto - June 1st, 2025 [June 1st, 2025]
- These triplets who graduated from Georgia Tech with neuroscience degrees head to medical school - 11Alive.com - June 1st, 2025 [June 1st, 2025]
- Gabe Newell co-founded a neuroscience company in 2019 and its first brain chip is expected to ship later this year - PC Gamer - June 1st, 2025 [June 1st, 2025]
- Next-Gen Painkiller Blocks Pain Without the High - Neuroscience News - May 21st, 2025 [May 21st, 2025]
- Inflammation Triggers Repetitive Behaviors in ASD and OCD - Neuroscience News - May 21st, 2025 [May 21st, 2025]
- Astrocytes Take Center Stage in Brain Function and Behavior - Neuroscience News - May 21st, 2025 [May 21st, 2025]
- Setting the SCENE for Neuroscience Breakthroughs - Mellon College of Science - Carnegie Mellon University - May 21st, 2025 [May 21st, 2025]
- Long COVID Brain Fog Linked to Inflammation and Stress Markers - Neuroscience News - May 21st, 2025 [May 21st, 2025]
- Warren Buffett Says Youre Too Focused on the Negative. Heres the Neuroscience Showing Hes Right - Inc.com - May 21st, 2025 [May 21st, 2025]
- Reading Fiction Boosts Empathy and Fights Loneliness - Neuroscience News - May 21st, 2025 [May 21st, 2025]
- Astrocytes, Not Neurons, Drive Brains Attention and Alertness - Neuroscience News - May 21st, 2025 [May 21st, 2025]
- Mapping Young Minds: The Neuroscience Behind Babilou Family Singapore's Revolutionary Education Model - PR Newswire - May 21st, 2025 [May 21st, 2025]
- Loneliness Linked to 24% Higher Risk of Hearing Loss - Neuroscience News - May 21st, 2025 [May 21st, 2025]
- Eureka Moments Double Memory by Rewiring the Brain - Neuroscience News - May 21st, 2025 [May 21st, 2025]
- Scientists use brain activity to predict StarCraft II skill in fascinating new neuroscience research - psypost.org - May 21st, 2025 [May 21st, 2025]
- Stress of Long Work Hours May Physically Alter the Brain - Neuroscience News - May 21st, 2025 [May 21st, 2025]
- The Neuroscience of Dopamine: How to Triumph Over Constant Wanting - Next Big Idea Club - May 12th, 2025 [May 12th, 2025]
- Verbal Abuse in Childhood Rewires the Developing Brain - Neuroscience News - May 12th, 2025 [May 12th, 2025]
- Heavy Social Media Use Linked to Believing and Spreading Fake News - Neuroscience News - May 12th, 2025 [May 12th, 2025]
- Brain Cells That Predict What Comes Next, Even When Its New - Neuroscience News - May 12th, 2025 [May 12th, 2025]
- The Temperature | Better happiness through neuroscience - The Colorado Sun - May 12th, 2025 [May 12th, 2025]
- Genes Strongly Influence When Babies Take Their First Steps - Neuroscience News - May 12th, 2025 [May 12th, 2025]
- Using Music to Detect Concussion in Kids - Neuroscience News - May 12th, 2025 [May 12th, 2025]
- Boosting Klotho Protein Slows Aging and Enhances Health - Neuroscience News - May 12th, 2025 [May 12th, 2025]
- Eye Movements Set the Speed Limit for What You Can See - Neuroscience News - May 12th, 2025 [May 12th, 2025]
- Seeing Is Believing: How We Judge AI as Creative or Not - Neuroscience News - May 12th, 2025 [May 12th, 2025]
- Exercise Boosts Stem Cell Therapy for Parkinsons - Neuroscience News - May 12th, 2025 [May 12th, 2025]
- Aspen Neuroscience Announces 6-Month ASPIRO Phase 1/2a Clinical Trial Results of Personalized Cell Therapy for Parkinson's Disease - BioSpace - May 12th, 2025 [May 12th, 2025]
- Sheffield Lab: Understanding the neuroscience of memories - University of Chicago News - April 27th, 2025 [April 27th, 2025]
- Prenatal Stress Leaves Lasting Molecular Imprints on Babies - Neuroscience News - April 27th, 2025 [April 27th, 2025]
- Dean Buonomano explores the concept of time in neuroscience and physics - The Transmitter - April 27th, 2025 [April 27th, 2025]
- Psychedelics May Reset Brain-Immune Link Driving Fear and Anxiety - Neuroscience News - April 27th, 2025 [April 27th, 2025]
- Infant Social Skills Thrive Despite Hardship - Neuroscience News - April 27th, 2025 [April 27th, 2025]
- From Cologne to Country Roads: One scientist's interdisciplinary journey to build bridges (and robotic insects) between neuroscience and engineering -... - April 27th, 2025 [April 27th, 2025]
- Eyes Reveal Intentions Faster Than We Think - Neuroscience News - April 27th, 2025 [April 27th, 2025]
- Immune Resilience Identified as Key to Healthy Aging and Longevity - Neuroscience News - April 27th, 2025 [April 27th, 2025]
- Energy Starvation Triggers Dangerous Glutamate Surges in the Brain - Neuroscience News - April 27th, 2025 [April 27th, 2025]
- WVU Rockefeller Neuroscience Institute first in U.S. to successfully test innovative brain-computer interface technology to decode speech and language... - April 27th, 2025 [April 27th, 2025]
- Microglia Reprogrammed to Deliver Precision Alzheimers Therapies - Neuroscience News - April 27th, 2025 [April 27th, 2025]
- Neuroscience Says Music Is an Emotion Regulation Machine. Heres What to Play for Happiness, Productivity, or Deep Thinking - Inc.com - April 19th, 2025 [April 19th, 2025]
- Early Maternal Affection Shapes Key Personality Traits for Life - Neuroscience News - April 19th, 2025 [April 19th, 2025]
- Elons new neuroscience major highlighted by Greensboro News & Record - Elon University - April 19th, 2025 [April 19th, 2025]
- Brain Blast event at St. Lawrence University teaches local students neuroscience - North Country Now - April 19th, 2025 [April 19th, 2025]
- AI Reveals What Keeps People Committed to Exercise - Neuroscience News - April 19th, 2025 [April 19th, 2025]
- The "Holy Grail" of Neuroscience? Researchers Create Stunningly Accurate Digital Twin of the Brain - The Debrief - April 19th, 2025 [April 19th, 2025]
- Annenberg School Vice Dean Emily Falk publishes book on the neuroscience of decision-making - The Daily Pennsylvanian - April 19th, 2025 [April 19th, 2025]
- Music-Induced Chills Trigger Natural Opioids in the Brain - Neuroscience News - April 19th, 2025 [April 19th, 2025]
- What We Value: The Neuroscience of Choice and Change - think.kera.org - April 19th, 2025 [April 19th, 2025]
- Kile takes top neuroscience post at Sutter Health as system pushes to align care, expand trials - The Business Journals - April 19th, 2025 [April 19th, 2025]
- A Grain of Brain, 523 Million Synapses, and the Most Complicated Neuroscience Experiment Ever Attempted - SciTechDaily - April 19th, 2025 [April 19th, 2025]
- Mild Brain Stimulation Alters Decision-Making Speed and Flexibility - Neuroscience News - April 19th, 2025 [April 19th, 2025]
- Cannabis studies were informing fundamental neuroscience in the 1970s - Nature - April 10th, 2025 [April 10th, 2025]
- To make a meaningful contribution to neuroscience, fMRI must break out of its silo - The Transmitter - April 10th, 2025 [April 10th, 2025]
- Steve Jobss Unexpected Secret to Being More Creative (Backed by Neuroscience) - Inc.com - April 10th, 2025 [April 10th, 2025]
- Challenging Decades of Neuroscience: Brain Cells Are More Plastic Than Previously Thought - SciTechDaily - April 10th, 2025 [April 10th, 2025]
- Q&A: Lundbecks head of R&D on letting biology speak in neuroscience - Endpoints News - April 10th, 2025 [April 10th, 2025]
- Why it's hard to study the neuroscience of psychedelics : Short Wave - NPR - April 10th, 2025 [April 10th, 2025]
- Fear Sync: How Males and Females Respond to Stress Together - Neuroscience News - April 10th, 2025 [April 10th, 2025]
- Chemotherapy Disrupts Brain Connectivity - Neuroscience News - April 10th, 2025 [April 10th, 2025]
- Newly awarded NIH grants for neuroscience lag 77 percent behind previous nine-year average - The Transmitter - April 10th, 2025 [April 10th, 2025]